- Tytuł:
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- Autorzy:
- Źródło:
- In Diabetes & Metabolism October 2019 45(5):409-418
Czasopismo naukowe